Prostate Cancer Market Size, Share, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

February 10 19:50 2021
Prostate Cancer Market Size, Share, Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of the male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide. Approximately one in nine men in the United States will be diagnosed with prostate cancer at some point in their lives. Furthermore, as per the American Cancer Society (2019), prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.

Treatment options for prostate cancers include mainly hormonal therapies (also known as androgen-deprivation therapy or ADT), chemotherapy, immunotherapy, radiation therapy, and surgery. For localized or locally advanced prostate cancer active surveillance, surgery, and radiation therapy are the three major treatment options.

Get FREE sample copy at: 
https://www.delveinsight.com/sample-request/prostate-cancer-market

The Prostate Cancer market report also covers emerging drugs, current treatment practices, Prostate Cancer market share of the individual therapies, current and forecasted Prostate Cancer Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Prostate Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Prostate Cancer Market

Prostate Cancer Market Key Facts

The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 cases in 2017, and are expected to increase during the study period (2017–2030).

The highest number of prevalent cases was observed in the United States with 3,170,339 cases in 2017 which will increase during the study period (2017–2030).

According to DelveInsight’s analysis, nearly 60 percent of Prostate Cancer cases diagnosed during localized or locally advanced stage (Stage I-III) in the United States

Among the EU-5 countries, the highest number of diagnosed prevalent cases of prostate cancer was found in Germany with 360,916 cases in 2017, followed by France and Italy.

Key Benefits of Prostate Cancer Market Report

  • Prostate Cancer market report provides an in-depth analysis of Prostate Cancer Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Prostate Cancer market report will help in developing business strategies by understanding the Prostate Cancer Market trends & developments, key players, and future market competition that will shape and drive the Prostate Cancer market in the upcoming years.

  • The Prostate Cancer market report covers Prostate Cancer’s current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Prostate Cancer market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Prostate Cancer Market
The total market size of Prostate Cancer in the 7MM was found to be around USD 6,798 million in 2017.

According to DelveInsight’s estimation, the overall market size in the seven major markets for Prostate Cancer is anticipated to increase during the forecast period. Prostate cancer market size is expected to witness a noteworthy growth rate owing to the rising prevalence of prostate cancer cases due to the rapidly aging population and growing awareness among people, expected better uptake of emerging therapies targeting specific mutations like PARP inhibitors and therapies targeting early-stage prostate cancer.

The Prostate Cancer market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Prostate Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Prostate Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Prostate Cancer Epidemiology
The Prostate Cancer epidemiology section covers insights about the historical and current Prostate Cancer patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Prostate Cancer Drugs Uptake and Key Market Players
The Prostate Cancer Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prostate Cancer market or expected to get launched in the market during the study period. The analysis covers Prostate Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The available therapeutics treatment options in the Prostate Cancer landscape aims to provide a cure to the patients suffering from this indication, however, there are several challenges that are yet to be tackled. The dynamics of the Prostate Cancer market are anticipated to change in the coming years owing to the rise in numbers of companies taking interest in the development of therapies for Prostate Cancer.

Prostate Cancer Companies:
AstraZeneca
Merck Sharp & Dohme
Bristol-Myers Squibb
Novartis
Myovant Sciences
Hoffmann-La Roche
Pfizer
Astellas Pharma
Innocrin Pharmaceutical
Clovis Oncology
And several other

Prostate Cancer therapies covered in the report include:
Lynparza
Opdivo
Lutathera
Relugolix
Niraparib
Ipatasertib
Talazoparib
ProstAtak
Keytruda
Rucaparib
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Prostate Cancer Competitive Intelligence Analysis

4. Prostate Cancer Market Overview at a Glance

5. Prostate Cancer Disease Background and Overview

6. Prostate Cancer Patient Journey

7. Prostate Cancer Epidemiology and Patient Population

8. Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Prostate Cancer Unmet Needs

10. Key Endpoints of Prostate Cancer Treatment

11. Prostate Cancer Marketed Products

12. Prostate Cancer Emerging Therapies

13. Prostate Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Prostate Cancer Market Outlook (7 major markets)

16. Prostate Cancer Access and Reimbursement Overview

17. KOL Views on the Prostate Cancer Market.

18. Prostate Cancer Market Drivers

19. Prostate Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports
Prostate Cancer Epidemiology Forecast
DelveInsight’s Prostate cancer – Epidemiology Forecast 2030 report delivers an in-depth understanding of the historical, and forecasted epidemiology of Prostate cancer in the 7MM.

Prostate Cancer Pipeline Insights
Prostate cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Prostate cancer market.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/